During the last few decades, the treatment of HIV-infected patients by highly active antiretroviral therapy, including protease inhibitors (PIs), has become standard. Here, we present results of analysis of a patient-derived, multiresistant HIV-1 CRF02_AG recombinant strain with a highly mutated protease (PR) coding sequence, where up to 19 coding mutations have accumulated in the PR. The results of biochemical analysis in vitro showed that the patient-derived PR is highly resistant to most of the currently used PIs and that it also exhibits very poor catalytic activity. Determination of the crystal structure revealed prominent changes in the flap elbow region and S1/S1' active site subsites. While viral loads in the patient were found to be high, the insertion of the patient-derived PR into a HIV-1 subtype B backbone resulted in reduction of infectivity by 3 orders of magnitude. Fitness compensation was not achieved by elevated polymerase (Pol) expression, but the introduction of patient-derived gag and pol sequences in a CRF02_AG backbone rescued viral infectivity to near wild-type (wt) levels. The mutations that accumulated in the vicinity of the processing sites spanning the p2/NC, NC/p1, and p6pol/PR proteins lead to much more efficient hydrolysis of corresponding peptides by patient-derived PR in comparison to the wt enzyme. This indicates a very efficient coevolution of enzyme and substrate maintaining high viral loads in vivo under constant drug pressure.

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc13012664

003      

CZ-PrNML

005      

20220614102147.0

007      

ta

008      

130404s2012 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1128/aac.00465-12 $2 doi

035    __

$a (PubMed)22644035

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Kozísek, Milan $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

245    10

$a Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease / $c M. Kozísek, S. Henke, KG. Sasková, GB. Jacobs, A. Schuch, B. Buchholz, V. Müller, HG. Kräusslich, P. Rezácová, J. Konvalinka, J. Bodem,

520    9_

$a During the last few decades, the treatment of HIV-infected patients by highly active antiretroviral therapy, including protease inhibitors (PIs), has become standard. Here, we present results of analysis of a patient-derived, multiresistant HIV-1 CRF02_AG recombinant strain with a highly mutated protease (PR) coding sequence, where up to 19 coding mutations have accumulated in the PR. The results of biochemical analysis in vitro showed that the patient-derived PR is highly resistant to most of the currently used PIs and that it also exhibits very poor catalytic activity. Determination of the crystal structure revealed prominent changes in the flap elbow region and S1/S1' active site subsites. While viral loads in the patient were found to be high, the insertion of the patient-derived PR into a HIV-1 subtype B backbone resulted in reduction of infectivity by 3 orders of magnitude. Fitness compensation was not achieved by elevated polymerase (Pol) expression, but the introduction of patient-derived gag and pol sequences in a CRF02_AG backbone rescued viral infectivity to near wild-type (wt) levels. The mutations that accumulated in the vicinity of the processing sites spanning the p2/NC, NC/p1, and p6pol/PR proteins lead to much more efficient hydrolysis of corresponding peptides by patient-derived PR in comparison to the wt enzyme. This indicates a very efficient coevolution of enzyme and substrate maintaining high viral loads in vivo under constant drug pressure.

650    _2

$a vysoce aktivní antiretrovirová terapie $7 D023241

650    _2

$a buněčné linie $7 D002460

650    _2

$a krystalografie rentgenová $7 D018360

650    _2

$a virová léková rezistence $x genetika $7 D024882

650    _2

$a geny gag $7 D015750

650    _2

$a geny pol $7 D015751

650    _2

$a HEK293 buňky $7 D057809

650    _2

$a HIV infekce $x farmakoterapie $x virologie $7 D015658

650    _2

$a HIV-proteasa $x chemie $x genetika $x metabolismus $7 D016333

650    _2

$a inhibitory HIV-proteasy $x terapeutické užití $7 D017320

650    _2

$a HIV-1 $x genetika $x izolace a purifikace $x fyziologie $7 D015497

650    _2

$a lidé $7 D006801

650    _2

$a molekulární sekvence - údaje $7 D008969

650    _2

$a mutace $7 D009154

650    _2

$a peptidové fragmenty $x genetika $7 D010446

650    _2

$a virová nálož $7 D019562

650    _2

$a genové produkty gag - virus lidské imunodeficience $x genetika $7 D054301

650    _2

$a genové produkty pol - virus lidské imunodeficience $x genetika $7 D054302

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486

700    1_

$a Henke, Sandra $u -

700    1_

$a Sasková, Klára Grantz $u -

700    1_

$a Jacobs, Graeme Brendon $u -

700    1_

$a Schuch, Anita $u -

700    1_

$a Buchholz, Bernd $u -

700    1_

$a Müller, Viktor $u -

700    1_

$a Kräusslich, Hans-Georg, $d 1958- $7 xx0273885

700    1_

$a Rezácová, Pavlína $u -

700    1_

$a Konvalinka, Jan $u -

700    1_

$a Bodem, Jochen $u -

773    0_

$w MED00009215 $t Antimicrobial agents and chemotherapy $x 1098-6596 $g Roč. 56, č. 8 (2012), s. 4320-30

856    41

$u https://pubmed.ncbi.nlm.nih.gov/22644035 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20130404 $b ABA008

991    __

$a 20220614102144 $b ABA008

999    __

$a ok $b bmc $g 975862 $s 810945

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2012 $b 56 $c 8 $d 4320-30 $i 1098-6596 $m Antimicrobial agents and chemotherapy $n Antimicrob Agents Chemother $x MED00009215

LZP    __

$a Pubmed-20130404